Article
A randomized Phase 2 study to compare erlotinib with or without bevacizumab in previously untreated patients with advanced non-small cell lung cancer with EGFR mutation.
Cancer - 1 Feb 2023
Lee Youngjoo, Kim Hye Ryun, Hong Min Hee, Lee Ki Hyeong, Park Keon Uk, Lee Geon Kook, Kim Hyae Young, Lee Soo-Hyun, Lim Kun Young, Yoon Sung Jin, Cho Byoung Chul, Han Ji-Youn
Abstract excerpt
BACKGROUND: This study evaluated whether an addition of bevacizumab to erlotinib improves clinical outcomes in patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC). METHODS: This is an open-label, multicenter, randomized Phase 2 study in South Korea. Chemonaïve patients with Stage IIIB/IV NSCLC with EGFR 19 deletion or L858R mutation were eligible. Asymptomatic brain metastasis (BM) was enrolled...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.